|Day's Range||53.93 - 54.76|
|52 Week Range||42.58 - 75.36|
|PE Ratio (TTM)||-42.63|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.
Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”